Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01111461 · ClinicalTrials.gov registry record · Phase 2
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT01111461 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 133 participants.
The verdict
NCT01111461, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
To assess the objective response rate (ORR: complete response + partial response \[CR+ PR\]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
Interventions
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01111461
The ClinicalTrials.gov registry entry for NCT01111461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenvatinib is the first listed.
NCT01111461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01111461 about?
NCT01111461 is a clinical study titled "Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression". To assess the objective response rate (ORR: complete response + partial response \[CR+ PR\]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
What is the current status of trial NCT01111461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2010-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01111461?
The interventions under investigation include: Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT01111461?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.